Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CELZ-201
- Development stage
- Phase 3
- Lead developer
- Creative Medical Technology
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intra-arterial, Injection
01
Overview
CELZ-201 is an allogeneic cell therapy candidate developed by Creative Medical Technology Holdings, derived from perinatal tissue stem cells. The therapy utilizes multi-potential stem cells characterized by self-renewal capabilities and low antigenicity. It is currently being evaluated in clinical trials for two primary indications: Type 1 Diabetes (T1D) and chronic lower back pain associated with degenerative disc disease. For T1D, the cells are administered via intra-arterial infusion into the dorsal artery of the pancreas to promote immunomodulation and potentially preserve beta-cell function. For lower back pain, the product (often referred to as CELZ-201-DDT) is delivered via paraspinal intramuscular injection to address inflammation and disc degeneration.
- Brand names
- StemSpineImmCelz
- Other names
- perinatal tissue-derived cellsAlloStem
Beyond the preview
Go deeper on CELZ-201.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CELZ-201.